Aspira Women’s Health has partnered with Cleveland Clinic to enhance AI-driven diagnostics aimed at ovarian cancer and endometriosis. This collaboration seeks to leverage advanced biomarker discovery and analytical models to improve women’s health diagnostics.
The partnership will focus on developing non-invasive tests, building on Aspira's existing OvaSuite, which helps assess ovarian cancer risk for over a million American women annually. Plans include expanding their diagnostic offerings by integrating microRNA and protein biomarkers, as well as creating a pioneering test for endometriomas, a prevalent form of endometriosis.
Dr. Kevin Elias from Cleveland Clinic emphasized the potential of combining multiomic biomarkers with AI analytics to revolutionize precision diagnostics in women's health. He noted that previous successes in ovarian cancer diagnostics indicate a broader application of this approach.
This collaboration signifies a strategic milestone for Aspira, as CEO Mike Buhle highlighted the aim to establish a leading platform in women’s health diagnostics. By merging Aspira's innovative technology with Cleveland Clinic's research capabilities, the initiative is poised to advance the field significantly.